This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Alert me on articles by topic  Social Bookmarking   What's this?

Richard A. Parker, MD; Erin E. Hartman, MS
From the Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, 330 Brookline Ave, LY318, Boston, MA 02215.

JAMA. 2001;286:2594.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In April 2000, at Psychiatry Grand Rounds, Gary Sachs, MD, discussed the epidemiology, natural history, diagnosis, and treatment of bipolar disorder.¹ Ms G, a 25-year-old woman, exhibited pressured speech, tangential thinking, and labile affect prior to her 2 psychiatric admissions. Due to her concern about weight gain with lithium carbonate, she was treated with divalproex and olanzapine. As an outpatient, Ms G was taking divalproex (750 mg, twice daily) and bupropion hydrochloride (150 mg, twice daily). She recognized the ongoing need for medications, but hoped to get off them over time. She wondered what other treatment modalities might be available to her.

Dr Sachs noted that Ms G, if untreated for bipolar disorder, faced a 15% risk of death by suicide. Without treatment, he predicted an almost 100% chance of a recurrence. Dr Sachs suggested that she would benefit from treatment with . . . [Full Text of this Article]

DR Z, THE PATIENT'S PSYCHIATRIST



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Increase in Allergic Respiratory Diseases : Survival of the Fittest?
Varner
Chest 2002;121:1308-1316.
ABSTRACT | FULL TEXT